Central India Chronicle

TIGIT Inhibitors Competitive Landscape Analysis, 2023 Updates | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies

 Breaking News
  • No posts were found

TIGIT Inhibitors Competitive Landscape Analysis, 2023 Updates | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies

May 16
20:45 2023
TIGIT Inhibitors Competitive Landscape Analysis, 2023 Updates  | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, TIGIT Inhibitors Competitive Landscape constitutes 18+ key companies continuously working towards developing 20+ TIGIT Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The TIGIT Inhibitors Competitive Landscape report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

TIGIT Inhibitors Competitive Landscape Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the TIGIT Inhibitors Market.

 

Some of the key takeaways from the TIGIT Inhibitors Competitive Landscape Report:

  • Companies across the globe are diligently working toward developing novel TIGIT Inhibitors treatment therapies with a considerable amount of success over the years. 
  • TIGIT Inhibitors companies working in the treatment market are Phio Pharmaceuticals, Biotheus, Compugen, Mereo BioPharma, GSK, Arcus Biosciences, BeiGene, Merck Sharp & Dohme, and others, are developing therapies for the TIGIT Inhibitors treatment 
  • Emerging TIGIT Inhibitors therapies such as – PH-804, PM 1021, COM902, Etigilimab, GSK4428859 (EOS884448), Domvanalimab, Ociperlimab, Vibostolimab, and others are expected to have a significant impact on the TIGIT Inhibitors market in the coming years.   
  • In February 2022, In order to treat patients with locally advanced (Stage III), unresectable non-small cell lung cancer whose disease has not progressed after receiving definitive platinum-based concurrent chemotherapy and radiation therapy, Arcus Biosciences started a Phase III, randomised, double-blind, multicentre, international study of Durvalumab plus Domvanalimab (AB154)
  • In October 2022, For the first-line treatment of patients with metastatic non-small cell lung cancer who do not have epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumour aberrations, Arcus Biosciences started a randomised, open-label, Phase III study to compare Zimberelimab and Domvanalimab with chemotherapy versus Pembrolizumab with chemotherapy

 

TIGIT Inhibitors Overview

One of the immunological checkpoints being studied as an immunotherapeutic target most recently is T-cell immunoreceptor with Ig and ITIM domains (TIGIT). TIGIT is a transmembrane glycoprotein receptor containing an ITIM in its cytoplasmic domain and a V-type domain that resembles an Ig. It is expressed on NK cells, Tregs, and activated and memory T cells.

 

Get a Free Sample PDF Report to know more about TIGIT Inhibitors Competitive Landscape Therapeutic Assessment-

https://www.delveinsight.com/sample-request/tigit-inhibitors-competitive-landscape

 

Emerging TIGIT Inhibitors Drugs Under Different Phases of Clinical Development Include:

  • PH-804: Phio Pharmaceuticals
  • PM 1021: Biotheus
  • COM902: Compugen
  • Etigilimab: Mereo BioPharma
  • GSK4428859 (EOS884448): GSK
  • Domvanalimab: Arcus Biosciences
  • Ociperlimab: BeiGene
  • Vibostolimab: Merck Sharp & Dohme

 

TIGIT Inhibitors Competitive Landscape Therapeutics Assessment

  • TIGIT Inhibitors Assessment by Product Type
  • TIGIT Inhibitors By Stage and Product Type
  • TIGIT Inhibitors Assessment by Route of Administration
  • TIGIT Inhibitors By Stage and Route of Administration
  • TIGIT Inhibitors Assessment by Molecule Type
  • TIGIT Inhibitors by Stage and Molecule Type

 

DelveInsight’s TIGIT Inhibitors Report covers around 20+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further TIGIT Inhibitors product details are provided in the report. Download the TIGIT Inhibitors Competitive Landscape report to learn more about the emerging TIGIT Inhibitors therapies

 

Some of the key companies in the TIGIT Inhibitors Therapeutics Market include:

Key companies developing therapies for TIGIT Inhibitors are – Arcus Biosciences, Merck & Co., Roche, Bristol-Myers Squibb, Agenus, Compugen, IGM Biosciences, Surface Oncology, RAPT Therapeutics, GammaDelta Therapeutics, Oncorus, BioNTech, Gilead Sciences, Nektar Therapeutics, BioAtla, Sanofi, Incyte Corporation, Immutep, F-star Therapeutics, CStone Pharmaceuticals, and others.

 

TIGIT Inhibitors Competitive Landscape Analysis:

The TIGIT Inhibitors Competitive Landscape report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of TIGIT Inhibitors with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for TIGIT Inhibitors Treatment.
  • TIGIT Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • TIGIT Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the TIGIT Inhibitors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about TIGIT Inhibitors drugs and therapies

 

TIGIT Inhibitors Competitive Landscape Market Drivers

  • Increase in research and development activities to develop TIGIT inhibitor in different therapy areas, no Approved Therapy are some of the important factors that are fueling the TIGIT Inhibitors Market.

 

TIGIT Inhibitors Competitive Landscape Market Barriers

  • However, high cost of therapies, precise mechanism of action is unclear and other factors are creating obstacles in the TIGIT Inhibitors Market growth.

 

Scope of TIGIT Inhibitors Competitive Landscape Drug Insight    

  • Coverage: Global
  • Key TIGIT Inhibitors Companies: Phio Pharmaceuticals, Biotheus, Compugen, Mereo BioPharma, GSK, Arcus Biosciences, BeiGene, Merck Sharp & Dohme, and others
  • Key TIGIT Inhibitors Therapies: PH-804, PM 1021, COM902, Etigilimab, GSK4428859 (EOS884448), Domvanalimab, Ociperlimab, Vibostolimab, and others
  • TIGIT Inhibitors Therapeutic Assessment: TIGIT Inhibitors current marketed and TIGIT Inhibitors emerging therapies
  • TIGIT Inhibitors Market Dynamics: TIGIT Inhibitors market drivers and TIGIT Inhibitors market barriers 

 

Request for Sample PDF Report for TIGIT Inhibitors Competitive Landscape Assessment and clinical trials

 

Table of Contents

1

TIGIT Inhibitors Report Introduction

2

TIGIT Inhibitors Executive Summary

3

TIGIT Inhibitors Overview

4

TIGIT Inhibitors- Analytical Perspective In-depth Commercial Assessment

5

TIGIT Inhibitors Competitive Landscape Therapeutics

6

TIGIT Inhibitors Late Stage Products (Phase II/III)

7

TIGIT Inhibitors Mid Stage Products (Phase II)

8

TIGIT Inhibitors Early Stage Products (Phase I)

9

TIGIT Inhibitors Preclinical Stage Products

10

TIGIT Inhibitors Therapeutics Assessment

11

TIGIT Inhibitors Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

TIGIT Inhibitors Key Companies

14

TIGIT Inhibitors Key Products

15

TIGIT Inhibitors Unmet Needs

16 

TIGIT Inhibitors Market Drivers and Barriers

17

TIGIT Inhibitors Future Perspectives and Conclusion

18

TIGIT Inhibitors Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services